Phase II trial of GDC-0084 in GBM underway
Kazia initiated a Phase II clinical study of GDC-0084 in March in patients with recently diagnosed GBM, an aggressive brain cancer. It had in-licensed the drug from Genentech in October 2016. GDC-0084 is an orally administered small molecule phosphoinositide 3-kinase (PI3K) inhibitor that targets an important growth signalling pathway in cancer cells. The drug was specifically developed to cross the blood-brain barrier and target GBM, which is an aggressive brain cancer with poor patient survival and for which there are few effective therapies.
Genentech conducted a Phase I trial of GDC-0084 in patients with advanced disease, which confirmed it readily crosses the blood-brain barrier and led to dose-dependent inhibition of tumour growth. Seven of the eight patients treated at the maximum tolerated dose of 45mg/day demonstrated levels of drug in the bloodstream that were associated with significant inhibition of tumour growth in preclinical models.
GBM: An aggressive brain cancer with few effective treatments
GBM is the most common and most aggressive primary malignant tumour of the brain and spinal cord. Approximately 11,500 patients are diagnosed with GBM each year in the US. GBM tumours are characterised by invasive and diffuse growth, which makes complete surgical removal difficult. Standard treatment for GBM entails surgical resection of the tumour followed by radiotherapy with concurrent chemotherapy with temozolomide (TMZ), followed by adjuvant chemotherapy with the same drug to treat the residual infiltrative component of the tumour. Despite this aggressive treatment the disease invariably returns, resulting in a five-year survival rate of only 5%.
In February the US FDA granted GDC-0084 Orphan Drug Designation (ODD), which is accorded to drugs that are considered promising treatments for rare (orphan) diseases. ODD provides for a minimum of seven years of market exclusivity and provides opportunities for grant funding, protocol assistance and FDA fee waivers.
GDC-0084 Phase II begins with a dose optimisation lead-in
Genentech’s Phase I study identified the MTD of GDC-0084 as 45mg/kg. This was conducted in very sick patients with late-stage disease and rapidly growing tumours whose disease had progressed despite having received one or more previous treatments.
In contrast, Kazia’s Phase II study will be conducted in newly diagnosed (first-line) patients who have undergone surgery to remove the bulk of the tumour and a course of chemoradiotherapy to further reduce the tumour burden. As these recently-diagnosed patients are expected to be in better overall health, Kazia is testing whether they are able to tolerate higher doses of GDC-0084 in a lead-in study before it moves on to the randomised stage of the trial. The open-label dose optimisation lead-in will initially treat patients at 60mg/kg, the highest dose that Genentech tested in its study. Depending on the side effects observed, the dose could be either increased to 75mg/kg or decreased to 45mg/kg, the current MTD.
Once the MTD in first-line patients is identified, an expansion cohort of 10-12 patients will be treated at that dose. These patients will undergo intensive monitoring to better understand the pharmacokinetic and toxicity profile of the drug, including the effect on major organs including the heart.
Patient monitoring will also include pharmacodynamic studies to confirm that the drug is having the desired pharmacological effects. These studies will likely include FDG-PET magnetic resonance imaging studies to determine whether the drug is affecting tumour metabolic activity in patients who have detectable tumours.
In parallel with the expansion cohort, Kazia will also investigate the effectiveness of alternative dosing regimens such as dosing every second day or four days on then three days off. These regimens could be considered as alternatives to dose reduction in patients who experience unacceptable drug toxicity at the MTD when it is administered every day. The trial design shown in Exhibit 2 was finalised in consultation with Kazia’s clinical advisers after a constructive meeting with the US FDA in September. The randomised component of the Phase II study will compare maintenance therapy with GDC-0084 vs standard-of-care TMZ in recently diagnosed GBM patients who have undergone standard therapy of surgery to remove the bulk of the tumour and a course radiation therapy (XRT) combined with TMZ. After completing XRT, 228 patients will be randomised to receive maintenance therapy with either GDC-0084 or TMZ to treat residual tumour cells and delay recurrence of the disease. The study will target the 61% of GBM patients where tumour cells have an unmethylated MGMT promoter, as they receive only minimal benefit from treatment with TMZ and are in urgent need of more effective therapies.
Exhibit 2: Revised GDC-0084 Phase II design includes a lead-in study
|
|
Source: Kazia 2017 AGM presentation
|
The open-label lead-in should provide an initial data readout in early 2019. As GDC-0084 is being used as an adjuvant therapy after the bulk of the tumour has been removed, many patients will not have measurable tumours at the start of the study, so they will not be able to be assessed for tumour response (shrinkage) according to the Response Assessment in Neuro-Oncology criteria. Therefore, the key criteria will be progression free survival (PFS) and overall survival (OS). FDG-PET responses will be assessed to see whether they are able to predict PFS or OS.
Exhibit 3 summarises the tumour responses for the patients in Genentech’s Phase I study of GDC-0084, grouped by dose cohort. Although none of the patients reached the 50% reduction in tumour size that would qualify as a partial response, a dose response in tumour growth was apparent, with much less tumour growth in patients treated at 45mg (the MTD) or higher doses. The dose response shown in Exhibit 3 provides encouragement that a higher dose of GDC-0084 may improve efficacy, which would increase the overall chance of success in the Phase II study. In addition to the reduction in tumour growth, 26% of patients showed a metabolic partial response on FDG-PET.
Exhibit 3: GBM patients in Phase I trial showed a trend to better disease control at higher doses of GDC-0084
|
|
Source: Wen et al 2016 ASCO poster. Note: Maximum tolerated dose was identified as 45mg (blue bars).
|
Unmethylated MGMT promoter unlikely to affect GDC-0084
Kazia is trialling GDC-0084 as adjuvant therapy in newly diagnosed GBM patients where the promoter region of the MGMT gene is unmethylated. In a seminal study reported in 2005, Hegi et al found that GBM patients with an unmethylated MGMT promoter received only minimal additional benefit when TMZ was added to radiotherapy in first-line treatment of newly diagnosed disease.
TMZ is an alkylating agent that adds a methyl group to purine bases of DNA, blocking DNA replication and leading to cell cycle arrest and apoptosis. MGMT can repair the DNA by removing the added methyl group, counteracting the cytotoxic effect of TMZ. Methylation of the MGMT promoter silences the gene, reducing MGMT activity in the cell and allowing TMZ to have its desired cytotoxic effect.
In contrast to TMZ, GDC-0084 blocks the PI3K signalling pathway, and does not interfere with DNA replication. Therefore, having an unmethylated MGMT promoter is not expected to interfere with the cancer-killing activity of GDC-0084. This is supported by preclinical studies performed by Genentech, which showed that GDC-0084 inhibited tumour growth in two different GBM tumour lines in which the MGMT promoter is unmethylated.
Accelerated approval could see GDC-0084 launched in 2023
There are no effective therapies for GBM in those patients whose tumour cells have an unmethylated MGMT promoter. Therefore, if the Phase II trial shows a meaningful improvement in PFS or OS in these patients, there is a good prospect that it could be eligible to seek accelerated approval based on the Phase II data, rather than waiting for a standard approval after completing a confirmatory Phase III trial.
Because of this, we have evaluated timelines for an accelerated approval of GDC-0084 as well as approval following a Phase III trial, as we described in our report in December.
Exhibit 4 shows a potential scenario where GDC-0084 gains accelerated approval in GBM after demonstrating a statistically significant and clinically meaningful improvement in PFS, with a potential market launch in Q2 CY23.
Exhibit 4: Assumed clinical trial and timeline for GDC-0084 accelerated approval
|
|
Source: Edison Investment Research
|
Under our second scenario, which assumes the results of the first Phase II trial indicate that GDC-0084 is efficacious against GBM, but that additional evidence from a second clinical trial is required before filing for approval, we forecast a potential market launch in Q4 CY26.
Exhibit 5: Assumed clinical trial and approval timeline for GDC-0084 under two-trial scenario
|
|
Source: Edison Investment Research
|
Background: PI3K and history of GDC-0084
PI3K is a promising target for GBM drug development
The PI3K signalling pathway plays a crucial role in cellular proliferation, metabolism, survival and apoptosis (programmed cell death). PI3K signalling is initiated by receptor tyrosine kinases or G-protein coupled receptors located at the cell surface, and by some oncogenic proteins such as Ras.
The PI3K pathway is frequently over-activated in cancer. The over-activation can occur through a variety of mechanisms including mutation and amplification of genes in the pathway, or by loss of function of the tumour suppressor PTEN, which is a negative regulator of PI3K signalling. Abnormal PI3K signalling is associated with over 80% of cases of the GBM.
The first approved cancer drugs that target the PI3K pathway were the rapamycin analogues everolimus and temsirolimus, which inhibit mTORC1. The PI3K inhibitor idelalisib (Zydelig, Gilead Sciences) was first approved by the FDA in 2014 and is approved to treat several types of leukaemia and lymphoma. Idelalisib is a selective inhibitor of the delta isoform of PI3K (PI3Kδ). A second PI3K inhibitor copanlisib (Aliqopa, Bayer) was approved for treating lymphoma in September 2017. The approval of these two drugs provides validation for PI3K as a target for anticancer drug development.
In March 2016, Gilead halted six combination trials of idelalisib in newly diagnosed patients due to serious side effects including deaths from infections. Idelalisib inhibits PI3Kδ, and this affects the immune system. In contrast, GDC-0084 most strongly inhibits PI3Kα and also inhibits mTOR, and has not caused similar toxic side effects in clinical trials.
As far as we are aware, Kazia is the only company that is developing a PI3K inhibitor in GBM. Novartis has previously trialled its pan-PI3K inhibitor buparlisib (BKM120) in a 76-patient Phase II study in GBM in combination with Avastin. The tumour response rate in that study was 6% (1/17) in patients who had undergone prior Avastin therapy and 36% (18/50) in patients who had not previously been treated with Avastin. However, in a Phase III study in breast cancer the drug was found to be effective but was considered too toxic to warrant further development, and buparlisib is not listed in Novartis’s current research pipeline. Novartis is instead studying the PI3Kα inhibitor alpelisib (BYL719) in a Phase III study in breast cancer patients with mutations in the PIK3CA gene, but is not trialling alpelisib GBM.
Cantrixil Phase I is expected to identify MTD in Q218
The Phase I study of Kazia’s third-generation benzopyran drug Cantrixil in ovarian cancer, which began in December 2016, is expected to report the MTD in Q2 CY18. Once the MTD has been identified, an expansion cohort of 12 additional ovarian cancer patients will be treated at the MTD.
While the primary purpose of the trial is to demonstrate safety and tolerability, patients will also be assessed for tumour responses. A readout of potential efficacy signals is expected later in CY18. The US FDA has granted Cantrixil orphan drug status for ovarian cancer.
Cantrixil is being administered as an intraperitoneal (IP) therapy delivered directly into the abdominal cavity. IP administration delivers higher concentration of the drug to the site of the tumour for longer periods, and studies of advanced ovarian cancer patients have shown a survival benefit for IP delivery compared to intravenous administration of chemotherapy drugs.
Researchers at Yale University have shown that Cantrixil is active in a stringent, clinically relevant rodent model of human ovarian cancer. Cantrixil is the first drug to show uniformly high potency against the Yale library of ovarian cancer stem cells collected from tumours that had stopped responding to chemotherapy.
High unmet need in ovarian cancer
Ovarian cancer accounts for 22,400 new cases and 14,100 deaths in the US each year, with a five-year survival rate of 47%. Worldwide there are an estimated 239,000 new cases and 152,000 deaths annually according to the International Agency for Research on Cancer with the highest rates coming from developed countries. The majority of those diagnosed already have distant metastases, which is associated with a 28.9% five-year survival rate (see Exhibit 6).
Exhibit 6: Ovarian cancer statistics
Stage |
% of cases |
Five-year survival |
Localised (confined to primary site) |
15 |
92.5% |
Regional (spread to regional lymph nodes) |
20 |
73.0% |
Distant (metastatic) |
60 |
28.9% |
Unknown |
6 |
25.1% |
Source: National Cancer Institute, Surveillance, Epidemiology and End Results Program
Patients who present with ovarian cancer are typically treated with surgery followed by a platinum based chemotherapy (such as paclitaxel and carboplatin). Unfortunately, around 70% of patients relapse in the first three years following therapy, although this figure is expected to improve, especially among the 10% of ovarian cancer patients with BRCA mutations, with the approval of the PARP inhibitor niraparib by the FDA as a maintenance therapy. PARP inhibitors are also used in those with BRCA mutations in later lines of therapy.
The situation is dire for patients who are platinum refractory or who become platinum resistant (a condition that eventually occurs in all surviving platinum-sensitive patients following repeated platinum courses). The current standard of care for platinum resistant or refractory patients is either PEGylated lysosomal doxorubicin (FDA approved in 1999) or topotecan (FDA approved in 1996), both of which typically have shown a response rate of 10-15%, PFS of approximately 3.5 months and overall survival of 12 months in large trials. This segment of the ovarian cancer population continues to be an unmet medical need and would likely be a key target for Cantrixil.
Kazia acquires Noxopharm shares in exchange for info and IP
In December Kazia reached agreement with Noxopharm (ASX:NOX) to provide certain technical information to support the development of Noxopharm’s lead programme, and released Noxopharm from future claims by Kazia against the intellectual property associated with that programme.
In exchange, Kazia was issued ~4.9% of Noxopharm’s stock (5.3m shares) and 3m unlisted options over NOX stock that expire in January 2020 and are exercisable at A$0.80 per share. The securities had an estimated market value of ~A$6.5m when they were issued in January, and the shares are subject to voluntary escrow until June.
The current CEO of Noxopharm, Dr Graham Kelly, was formerly chairman and CEO of Kazia (then known as Novogen), and resigned from the company in July 2015.
Based on the NOX share price of A$0.83 on 4 May, the current market value of the 5.3m NOX shares is A$4.4m. Once the escrow agreement expires in June, Kazia would have the option of raising funds through the sale of the shareholding or through a loan secured against the shares.
Anti-tropomyosin programme de-emphasised
In February 2017, Kazia was awarded a grant of up to A$3m over three years by the Australian government to develop next-generation anti-tropomyosin (ATM) therapies for cancer treatment. Kazia is the lead partner in the collaboration that also involves the University of New South Wales and the privately held CRO, ICP Firefly. Kazia was expected to contribute A$1m and the University of New South Wales to contribute A$0.3m to funding the project.
For the time being Kazia has suspended investment into discovery research, including the next-generation ATM programme, as it focuses its resources on GDC-0084 and Cantrixil.
Out-licensed preclinical benzopyran programme to HBLS
As part of its strategy to focus on clinical development programmes, in November Kazia out-licensed its preclinical benzopyran and ad-het programmes, including Trilexium, to Heaton-Brown Life Sciences (HBLS). Kazia retains a commercial interest in the preclinical assets, through a 10% shareholding in HBLS plus milestone and royalty payments linked to successful development. Kazia retains all rights relating to Cantrixil, and the agreement prevents the development of Trilexium as a therapy for ovarian cancer.
HBLS is a private company established by Dr Andrew Heaton and Dr David Brown, who are both former employees of Kazia and co-founders of the Triaxial technology that underpinned the third generation-benzopyran and ad-het programmes. We do not know whether HBLS has the necessary financial resources to pursue clinical development of the benzopyran programme.
We have revised our valuation of Kazia to include the current market value of the Noxopharm shareholding, and have rolled forward the DCF model in time, including switching to end FY18e cash balance. When calculating value per share we have taken in to account the A$1.25m of shares that will be payable to the Glioblast vendors when the first patient is dosed in the Phase II trial.
We have valued GDC-0084 under two different development scenarios for GBM – in addition to our base case valuation, which assumes market launch in 2026 following completion of a Phase III trial, we have valued GDC-0084 assuming accelerated approval with a launch in 2023.
As a result of these changes, our base case valuation of Kazia has increased to A$73m (previously A$69m) or A$1.46/share undiluted (vs A$1.43 per consolidated share) and A$1.47/share after diluting for options and convertible notes. Note that the per-share value does not account for the Glioblast milestone payment (A$1.25m of shares) potentially payable in FY21 on successful completion of Phase II. Kazia is also listed on NASDAQ under the code KZIA, with each NASDAQ-listed ADR representing 10 ordinary shares. Our undiluted base case valuation equals US$11.10 per ADR at current exchange rates.
Our base case valuation assumes a 40% likelihood that GDC-0084 is out-licensed to a marketing partner in 2021 after reporting positive PFS data from the Phase II trial, in a deal that includes US$20m upfront and US$120m in clinical and regulatory milestone payments. We also assume that Kazia pays a royalty of 10% of net sales to Genentech and that global sales for GBM reach US$1,050m in 2030.
Our valuation is based on a risk-adjusted discounted cash flow model. Our cash flow forecasts extend to 2035, but do not include any terminal valuation and apply a 12.5% discount rate. In calculating the diluted NPV/share, we assume that the A$0.5m remaining balance of the Triaxial convertible note is converted to 1.9m shares on completion of Phase II trials in 2021 (the A$1.5m convertible note was issued as part of the purchase of Triaxial and its third-generation benzopyran technology, A$0.9m was converted in H117, A$0.14m was extinguished as part of the settlement with Noxopharm).
Exhibit 7 shows our base case market assumptions for GDC-0084 and Cantrixil and the contribution of product royalties and milestone payments to the rNPV, which have not changed since our last note. We have offset the risk-adjusted trial cost against milestone revenue for each drug, rather than against royalty revenue. This understates the contribution of the milestone payments to the rNPV and overstates the contribution of royalties.
Exhibit 7: Kazia base case valuation (assumes confirmatory GDC-0084 pivotal trial required)
|
Likelihood (%) |
rNPV (A$m) |
rNPV/ share (A$) |
Assumptions |
GDC-0084; GBM |
25% |
16.0 |
$0.32 |
Global peak sales* of US$1,050m from GBM (11,500 US cases/year, 61% unmethylated MGMT promoter, 80% penetration); pricing of US$50k. Global sales 2x US sales; launch 2026; assumes receives 15% royalty on sales, pays away 10% of royalty to Genentech. |
GDC-0084; brain metastases in HER2+ breast cancer |
20% |
6.7 |
$0.13 |
Global peak sales of US$570m (233,000 US breast cancer cases/year, 37% HER2+, 7% develop brain metastases, 50% penetration); pricing of US$50k. Global sales 2x US sales; launch 2026; assumes receives 15% royalty on sales, pays away 10% of royalty to Genentech. |
Ovarian and other abdominal cancers: Cantrixil |
10% |
25.9 |
$0.52 |
Global peak sales of US$680m from ovarian cancer (14,300 US deaths/year, 30% penetration) and bowel cancer (50,300 US deaths, 25% develop malignant ascites, 20% penetration); pricing of US$50k. Global sales 2x US sales; launch 2025; assumes receives 15% royalty on sales, pays away 5% of revenue to Yale. |
GDC-0084 milestones |
|
9.4 |
$0.19 |
Assumes potential licensing upfronts and milestones total US$140m (US$127m net of payments to Glioblast and Genentech; US$38m after risk adjustment). |
Cantrixil milestones |
|
17.0 |
$0.34 |
Assumes potential licensing upfronts and milestones total US$140m (US$23m after risk adjustment); assumes 5% of upfront and milestone payment paid away to Yale. |
SG&A |
|
-9.4 |
-$0.19 |
|
Portfolio total |
|
65.6 |
$1.31 |
|
Noxopharm shares market value |
|
4.1 |
$0.08 |
|
Cash (30 June 2018) |
|
3.6 |
$0.07 |
|
Enterprise total |
|
73.3 |
$1.46 |
|
Source: Edison Investment Research. Note: *Peak sales in actual dollars in forecast year. We assume that the addressable markets grow at 4% per year. Launch dates listed are calendar years (in some cases the launch will be in the following financial year to the calendar year stated).
We have also valued Kazia under an alternative accelerated approval scenario for GDC-0084, which assumes a market launch in 2023 and that Kazia receives a higher 20% royalty rate and a larger US$40m upfront payment because the data are ready for filing, with other deal terms the same as for the post-Phase III approval base case scenario. Exhibit 8 shows that accelerated approval for GDC-0084 would increase our valuation for Kazia to A$133m (previously A$127m) or A$2.65/share (undiluted).
Exhibit 8: Kazia valuation in GDC-0084 accelerated approval scenario
|
Likelihood (%) |
rNPV (A$m) |
rNPV/ share (A$) |
Assumptions |
GDC-0084 – GBM |
25% |
60.3 |
$1.20 |
As per Exhibit 7, except 2023 launch (vs 2026) and 20% gross royalty on sales (vs 15%). |
GDC-0084 – brain metastases in HER2+ breast cancer |
20% |
13.3 |
$0.27 |
As per Exhibit 7, except 20% gross royalty on sales (vs 15%). |
GDC-0084 milestones |
|
18.3 |
$0.37 |
Assumes potential licensing upfronts and milestones total US$160m (US$147m net of payments to Glioblast and Genentech; US$48m after risk adjustment). Milestones received earlier than base case (final milestone in 2023 vs 2026). |
GDC-0084 total |
|
91.9 |
$1.83 |
|
Remainder of portfolio |
|
33.5 |
$0.67 |
|
Portfolio total |
|
125.4 |
$2.50 |
|
Noxopharm shares market value |
|
4.1 |
$0.08 |
|
Cash (30 June 2018) |
|
3.6 |
$0.07 |
|
Enterprise total |
|
133.1 |
$2.65 |
|
Source: Edison Investment Research. Note: Launch dates listed are calendar years.